Zacks Investment Research Upgrades Ra Pharmctl Inc (RARX) to Hold
Zacks Investment Research upgraded shares of Ra Pharmctl Inc (NASDAQ:RARX) from a sell rating to a hold rating in a research note published on Tuesday.
According to Zacks, “Ra Pharmaceuticals, Inc. is a biopharmaceutical company. It involved in the discovery and development of novel therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. Ra Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “
A number of other equities analysts have also recently commented on the company. Jefferies Group LLC reaffirmed a buy rating and issued a $25.00 target price on shares of Ra Pharmctl in a report on Friday, July 14th. Royal Bank Of Canada initiated coverage on Ra Pharmctl in a report on Thursday, September 14th. They issued an outperform rating and a $21.00 target price on the stock. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $26.00.
Shares of Ra Pharmctl (NASDAQ:RARX) opened at 14.60 on Tuesday. The company’s market capitalization is $330.09 million. Ra Pharmctl has a 1-year low of $12.05 and a 1-year high of $24.12. The company’s 50 day moving average price is $14.70 and its 200-day moving average price is $14.70.
Ra Pharmctl (NASDAQ:RARX) last announced its earnings results on Wednesday, August 9th. The company reported ($0.56) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.50) by ($0.06). On average, equities analysts forecast that Ra Pharmctl will post ($2.31) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Zacks Investment Research Upgrades Ra Pharmctl Inc (RARX) to Hold” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/30/zacks-investment-research-upgrades-ra-pharmctl-inc-rarx-to-hold.html.
A number of large investors have recently bought and sold shares of the business. California State Teachers Retirement System raised its holdings in Ra Pharmctl by 26.1% during the second quarter. California State Teachers Retirement System now owns 20,800 shares of the company’s stock valued at $390,000 after acquiring an additional 4,300 shares during the period. The Manufacturers Life Insurance Company raised its holdings in Ra Pharmctl by 30.6% during the second quarter. The Manufacturers Life Insurance Company now owns 10,860 shares of the company’s stock valued at $204,000 after acquiring an additional 2,543 shares during the period. State Street Corp raised its holdings in Ra Pharmctl by 40.3% during the second quarter. State Street Corp now owns 151,063 shares of the company’s stock valued at $2,830,000 after acquiring an additional 43,376 shares during the period. Nexthera Capital LP bought a new stake in Ra Pharmctl during the second quarter valued at about $1,912,000. Finally, Fred Alger Management Inc. raised its holdings in Ra Pharmctl by 83.3% during the second quarter. Fred Alger Management Inc. now owns 33,000 shares of the company’s stock valued at $618,000 after acquiring an additional 15,000 shares during the period. 66.26% of the stock is currently owned by institutional investors and hedge funds.
About Ra Pharmctl
Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Ra Pharmctl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmctl Inc and related stocks with our FREE daily email newsletter.